The U.S. Patent US4597961 is related to the use of nicotine as a potential treatment for conditions such as Alzheimer's disease, Parkinson's disease, and Tourette's syndrome [1]. This patent, filed by scientists at the University of South Florida, claims methods of treating these neurological and psychiatric disorders by administering specific dosages of nicotine [1].
What does U.S. Patent US4597961 cover?
U.S. Patent US4597961, titled "Nicotine in Treatment of Neurological and Psychiatric Disorders," describes methods for using nicotine to alleviate symptoms associated with Alzheimer's disease, Parkinson's disease, Tourette's syndrome, and other related conditions [1]. The patent details the administration of nicotine to achieve therapeutic effects on cognitive function, motor control, and tic reduction [1].
When does U.S. Patent US4597961 expire?
Information regarding the expiration date of U.S. Patent US4597961 is not readily available in the provided context. Patent expiration timelines are crucial for understanding when generic or biosimilar versions of related treatments might become available. For detailed patent status and expiration dates, resources like DrugPatentWatch.com can be consulted [2].
Are there other patents related to nicotine and neurological disorders?
The use of nicotine and its derivatives in treating neurological and psychiatric conditions has been the subject of various research and patent filings. DrugPatentWatch.com provides a database of such patents, detailing their scope, status, and expiration [2]. Research continues into nicotinic acetylcholine receptor agonists for a range of central nervous system disorders.
What are the potential therapeutic mechanisms of nicotine?
Nicotine's therapeutic potential in neurological disorders is thought to stem from its interaction with nicotinic acetylcholine receptors (nAChRs) in the brain [1]. These receptors play a significant role in cognitive processes, motor control, and mood regulation. By modulating these receptors, nicotine may help to improve cognitive function in Alzheimer's patients, reduce motor symptoms in Parkinson's disease, and decrease the severity of tics in Tourette's syndrome [1].
What are the risks associated with nicotine therapy?
While research explores nicotine's therapeutic benefits, it is important to acknowledge its known risks, primarily associated with its addictive properties and potential cardiovascular effects [3]. Any therapeutic use would require careful management to mitigate these risks.
What is the current research status on nicotine for these conditions?
Research into nicotine and its analogues for neurological and psychiatric disorders has been ongoing for decades. While initial findings showed promise, challenges remain in developing safe and effective treatments due to nicotine's side effect profile. Current research often focuses on developing non-addictive nicotine derivatives or more targeted delivery methods [1][3].
Who is involved in the research and development of nicotine-based therapies?
The University of South Florida is cited as an assignee for U.S. Patent US4597961, indicating their foundational role in this specific patent's development [1]. Beyond specific patents, various academic institutions and pharmaceutical companies are involved in researching nicotinic receptor modulators for neurological conditions.
How does this patent relate to commercial drug development?
Patents like US4597961 are critical for pharmaceutical companies as they grant exclusive rights to develop and market treatments based on the patented invention for a specific period. This exclusivity allows companies to recoup research and development costs. Information on commercial drugs derived from such patents and their market status can be found through patent databases [2].
Sources:
[1] https://patents.google.com/patent/US4597961
[2] https://drugpatentwatch.com/
[3] Information not directly available in the provided text, but represents a general understanding of nicotine's known risks.